Zidovudine reduces intrathecal immunoactivation in patients with early human immunodeficiency virus type 1 infection.

摘要: Objective: To evaluate the effect of zidovudine on human immunodeficiency virus type 1 (HIV-1)—associated central nervous system infection in Centers for Disease Control and Prevention stage II or III disease. Design: In an open-ended trial, patients received 500 mg twice a day 12 months. Lumbar punctures, neurological, neuropsychological, neuroradiological examinations were repeatedly performed during trial period compared with pretrial values. 11 posttrial neurological follow-up 10 to 20 months was performed. Patients: Initially, 14 volunteers disease intrathecal synthesis HIV-1—specific antibodies enrolled. Additionally, had slight neuropsychological disturbance brain atrophy unrelated other agents than HIV-1. Two dropped out because poor compliance. Main Outcome Measures: Intrathecal systemic immune virological responses, cognitive performance, images monitored. Results: After 6 weeks therapy, initial low-grade pleocytosis elevated levels β 2 -microglobulin, both cerebrospinal fluid serum samples, declined. HIV-1 antibody could no longer be detected half after therapy. Patients defective cognition transiently improved speed flexibility Slight atrophic changes, however, remained unchanged. Conclusions: Zidovudine reduces immuno-activation improves functioning HIV-1-infected subjects who show evidence involvement by but are otherwise asymptomatic.